Researchers at the University of California, Davis have developed a process to localize anticoagulation drugs for treatment of inflammation and atrial fibrillations.
Currently, patients being treated for atrial fibrillation must also be treated for potential blood clots due to inefficient blood flow. Although effective, these drugs widely affect the blood concentration of a patient and put them at risk of severe bleeding through ruptured blood vessels. In addition, these treatments do not have any noninvasive ways to assess a patient's risk of developing atrial fibrillation post-surgery for coronary bypass patients.
Researchers at the University of California, Davis have developed a process to both localize anticoagulation drugs to inflamed sites, and obtain image inflammatory markers in the inflamed areas. This development localizes the treatment and prevention of blood clotting to at risk sites, such as the left atrial appendage. This treatment targets specific biomarkers and cell types, and allows for higher concentrations of anticoagulants at the treatment site. Therefore, patients would not require blood thinning, lowering the risk of offsite bleeding. In addition, the imaging technique developed allows for a non-invasive method for diagnosing atrial fibrillation.